Methicillin-Resistant Staphylococcus aureus Bacteremia Treated With Vancomycin Calculated by Area-Under-the-Curve in...

Area of Science:

• Pharmacology
• Infectious Diseases
• Clinical Pharmacy

Background:

• Vancomycin is the recommended first-line treatment for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia.
• Current dosing guidelines recommend area-under-the-curve (AUC) based dosing with an assumed minimum inhibitory concentration (MIC) of 1 mcg/mL via broth microdilution.
• However, higher MICs may impact treatment effectiveness.

Purpose of the Study:

• To compare the effectiveness of AUC-based versus trough-based vancomycin dosing in patients with MRSA bacteremia and an MIC > 1 mcg/mL.
• To evaluate differences in treatment failure, nephrotoxicity, and drug exposure between the two dosing strategies.

Main Methods:

• Retrospective, observational cohort study comparing vancomycin dosing by AUC or trough.
• Patient data collected between January 1, 2017, and September 1, 2022.
• Primary outcome: composite of treatment failure (persistent bacteremia, 90-day mortality, 30-day relapse/readmission). Secondary outcomes: nephrotoxicity, length of stay, MIC, and AUC exposure.

Main Results:

• No statistically significant difference in treatment failure was observed between the trough and AUC groups (41.7% in both).
• Secondary outcomes, including nephrotoxicity incidence and median AUC exposure, were similar between the groups.
• Numerically higher vancomycin exposure and nephrotoxicity were noted in the trough dosing group.

Conclusions:

• Neither AUC-based nor trough-based vancomycin dosing demonstrated a statistically significant difference in treatment failure for MRSA bacteremia with an Etest MIC > 1 mcg/mL.
• AUC-based dosing may potentially limit vancomycin exposure and reduce nephrotoxicity without compromising treatment efficacy.
• Further research may be warranted to optimize vancomycin dosing strategies for specific patient populations and MIC values.